PSICOFÁRMACOS NO TRATAMENTO DA DEPENDÊNCIA QUÍMICA: UMA REVISÃO

Autores

  • Marcos Fernando Knevitz Universidade Católica Dom Bosco - UCDB
  • Danieli Fernanda Buccini Universidade Católica Dom Bosco - UCDB

DOI:

https://doi.org/10.33362/ries.v7i1.1124

Palavras-chave:

Psicofármacos. Tratamento. Dependência Química. Comorbidades. Fissura.

Resumo

A farmacoterapia atua no tratamento da dependência química, complementando outras atividades que procuram melhorar os aspectos da vida dos pacientes. Os tratamentos farmacológicos têm por finalidade prevenir ou atenuar a síndrome de abstinência, diminuir a fissura e atuar no tratamento das comorbidades. O objetivo deste trabalho foi revisar o modo de atuação dos psicofármacos no tratamento das dependências, além de verificar sua relação com as principais classes de substâncias de abuso. A metodologia utilizada foi a revisão sistemática, utilizando como critérios de avaliação a população envolvida de adultos e adolescentes, a intervenção referindo o uso de psicofármacos no tratamento da dependência química e como desfecho os efeitos dos medicamentos nos indivíduos. Apesar de apresentarem bons resultados no tratamento da dependência de álcool, nicotina e opioides, importantes adições como maconha, cocaína e seus derivados ainda não possuem tratamentos farmacológicos com evidências positivas comprovadas que permitam sua utilização. Desse modo, são necessárias mais pesquisas para a busca de novos medicamentos que auxiliem o tratamento dessas dependências, além da participação ativa do paciente no processo.

Palavras-chave: Psicofármacos. Tratamento. Dependência Química. Comorbidades. Fissura.

 

ABSTRACT: Pharmacotherapy works in the treatment of chemical dependency, complementing other activities which seek to improve the quality of patients' lives. Pharmaceutical treatments aim to prevent or attenuate a withdrawal syndrome, reduce craving and act in the treatment of comorbidities. The objective of this study is to review the way psychoactive drugs work in dependence treatment, as well as to verify their relationships with the major classes of substances of abuse. The methodology used was the systematic review, using as evaluation criteria the population of adults and teenagers engaged, the intervention related to the use of psychotropic drugs in the treatment of chemical dependence and as an outcome the effects of the drugs in the individuals. Despite the fact that it presents good results in treatment of alcohol dependence, nicotine and opioids, important additions such as marijuana, cocaine and its derivatives are not pharmacological treatments with proven positive evidence which allow its use yet. In this way, further studies are needed for the searching of new drugs for the treatment of addictions, besides the active participation of the patient in the process.

Keywords: Psychopharmaceuticals. Treatment. Chemical Dependency. Comorbidities. Craving.

Biografia do Autor

Marcos Fernando Knevitz, Universidade Católica Dom Bosco - UCDB

Farmacêutico pela Universidade Luterana do Brasil (ULBRA). Mestre em Saúde Coletiva (ULBRA).

Danieli Fernanda Buccini, Universidade Católica Dom Bosco - UCDB

Bióloga pela Universidade Anhanguera (UNIDERP) Mestre em Biotecnologia pela Universidade Católica Dom Bosco (UCDB)

Referências

BERRIDGE, K. C; ROBINSON, T. E; ALDRIDGE, J. W. Dissecting components of reward: liking, wanting, and learning. Curr Opin Pharmacology, n. 9, p. 65–73, 2009.

BRADY, K. T. et al. Treatment of Patients Comorbid for Addiction and Other Psychiatric Disorders. Current Psychiatry Reports, n.9, p. 374-80, 2007.

BROWN, E. S. et al. Naltrexone in patients with bipolar disorder and alcohol dependence. Depress Anxiety, n. 23, p. 492–95, 2006.

BROWN, E. S. et al. Lamotrigine for bipolar disorder and comorbid cocaine dependence: a replication and extension study. J Affect Disord, n. 93, p. 219–22, 2006.

BRUNETTE, M. F. et al.: Clozapine use and relapses of substance use disorder among patients with co-occurring schizophrenia and substance use disorders. Schizophr Bull, 32, p. 637–43, 2006.

DALLEY, J. W; EVERITT, B. J. Dopamine receptors in the learning, memory and drug reward circuitry. Semin Cell Dev Biol, n. 20, p. 403–10, 2009.

DEGENHARDT, L. et al. Global burden of disease attributable to illicit drug use and dependence: findings from the Global Burden of Disease Study 2010. Lancet, n. 382, p. 1564-74, 2013.

DOUAIHY, A. B; KELLY, T. M; SULLIVAN, C. Medications for Substance Use Disorders. Social Work in Public Health, n. 28, p. 264–78, 2013.

FIGLIE, N. B; BORDIN, S; LARANJEIRA, R. Aconselhamento em dependência química. 2 ed. São Paulo, Ed Roca. 2010.

FONSECA, V. A. S; LEMOS, T. Farmacologia na dependência química. In: DIHL, A; CORDEIRO, D. C; LARANJEIRA, R. Dependência química: prevenção, tratamento e políticas públicas. São Paulo, Ed. Artmed. p. 25-34, 2011.

FORRAY, A. SOFUOGLU, M . Future pharmacotherapies for substance use disorders. British Journal of Clinical Pharmacology, 77(2), p. 382-400, 2012.

FURST, S; RIBA, P; AL-KHRASANI, M. New approach to the neurobiological mechanisms of addiction. Neuropsychopharmacologia Hungarica, 15(4), p. 189-205, 2013.

HEIDBREDER, C. A; NEWMAN, A. H. Current perspectives on selective dopamine D(3) receptor antagonists as pharmacotherapeutics for addictions and related disorders. Ann N Y Acad Sci, 1187, p. 4–34, 2010.

HORDER, J. et al. Reduced neural response to reward following 7 days treatment with the cannabinoid antagonist rimonabant in healthy volunteers. Int J Neuropsychopharmacol, n.13, p. 1103–13, 2010.

HUGHES, J. R; STEAD, L.F; LANCASTER, T. Antidepressants for smoking cessation. Cochrane Database of Systematic Reviews, 1. n. CD000031. DOI: 10.1002 /14651858. CD000031.pub3, 2007.

JASINSKI, D. R; KRISHNAN, S. Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse. J Psychopharmacology, 9(23), p. 419–27, 2009.

JOHNSON, B. A. et al. Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA, 298(14), p. 1641-51, 2007.

KELLY, T. M; DALEY, D. C; DOUAIHY, A. B. Treatment of substance abusing patients with comorbid psychiatric disorders. Addictive Behaviors, n. 37, p. 11–24, 2012.

KHOO, S. Y. S; BROWN, R. M. Orexin/Hypocretin Based Pharmacotherapies for the Treatment of Addiction: DORA or SORA? CNS Drugs, n. 28, p. 713–30, 2014.

KOOB, G. F; VOLKOW N. D. Neurocircuitry of addiction. Neuropsychopharmacology, n. 35, p. 217–38, 2010.

LADER, M. Effectiveness of benzodiazepines: do they work or not? Expert Rev Neurother, 8(8), p. 1189- 91, 2008.

LEVIN, F. R. et al. Treatment of cocaine dependent treatment seekers with adult ADHD: double-blind comparison of methylphenidate and placebo. Drug Alcohol Depend, n. 87, p. 20–9, 2007.

LINGFORD-HUGHES, A. R. et al. BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP. Journal of Psychopharmacology, 26(7), p. 899–952, 2012.

LONGO, M. et al. Randomized controlled trial of dexamphetamine maintenance for the treatment of methamphetamine dependence. Addiction, n.105, p. 146–54, 2010.

MARTINEZ-RAGA, J; KNECHT, C; CEPEDA, S. Modafinil: a useful medication for cocaine addiction? Review of the evidence from neuropharmacological, experimental and clinical studies. Rev. Curr Drug Abuse, n.1, p. 213–21, 2008.

NARVAEZ, J. C. M. et al. Psychiatric and substance use comorbidities associated with lifetime crack cocaine use in young adults in the general population. Comprehensive Psychiatry, n. 55, p. 1369–376, 2014.

PENG, X. Q. The preferential dopamine D3 receptor antagonist S33138 inhibits cocaine reward and cocaine triggered relapse to drug-seeking behavior in rats. Neuropharmacology, n. 56, p. 752–60, 2009.

POLYDOROU, P; LEVIN, F. R. Treating alcohol dependence: When and how to use 4 medications. Current Psychiatry, 7(2), p. 25-37, 2008.

RIGGS, P. D. et al. A random¬ized controlled trial of fluoxetine and cognitive behavioral therapy in adolescents with major depression, behavior problems, and substance use disorders. Arch Pediatr Adolesc Med, n. 161, p. 1026–34, 2007.

RIGGS, P. et al. Comorbid Psychiatrie and Substance Abuse Disorders: Recent Treatment Research. Substance Abuse, 29 (3), p. 51-63, 2008.

SCHMIDT, H. D; PIERCE, R. C. Cocaine induced neuroadaptations in glutamate transmission: potential therapeutic targets for craving and addiction. Ann N Y Acad Sci, 1187, p. 35–75, 2010.

SHOPTAW, S. Bupropion hydrochloride versus placebo, in combination with cognitive behavioral therapy, for the treatment of cocaine abuse/dependence. Journal Addict Dis, n. 27, p. 13–23, 2008.

SMELSON, D. A. et al. Antipsychotic treatment discontinuation among individuals with schizophrenia and co-occurring substance use. J Clin Psychopharmacology, n. 26, p. 666–67, 2006.

SOFUOGLU, M; KOSTEN, T. R. Emerging pharmacological strategies in the fight agaist cocaine addiction. Expert Opin Emerg Drugs, 11(1), p. 91-98, 2006.

TONSTAD, S; DAVIES, S; FLAMMER, M. et al. Psychiatric adverse events in randomized, double-blind, placebo-controlled clinical trials of var¬enicline: a pooled analysis. Drug Saf, n. 33, p. 289–301, 2010.

VALERIANE, G. et al. Olanzapine as the ideal “trip terminator”? Analysis of online reports relating to antipsychotics’ use and misuse following occurrence of novel psychoactive substance-related psychotic symptoms Hum. Psychopharmacology Clin Exp. n. 30, p. 249–54, 2015.

VOLKOW, N. D; FOWLER, J. S; WANG, G. J. Positron emission tomography and single-photon emission computed tomography in substance abuse research. Semin. Nucl. Med, 33(2), p. 114-28, 2003.

UNITED NATIONS OFFICE ON DRUGS AND CRIME (UNODC). World Drug Report: executive summary. Viena, 2015. Disponível em: <http://www.unodc .org/documents /wdr2015/world_drug_report_2015.pdf> acesso em: 16 ago. 2016.

WILENS, T. E; FUSILLO, E. When ADHD and Substance Use Disorders Intersect: Relationship and Treatment Implications. Current Psychiatry Reports, n. 9, p. 408–14, 2007.

Downloads

Publicado

2018-11-29

Como Citar

Knevitz, M. F., & Buccini, D. F. (2018). PSICOFÁRMACOS NO TRATAMENTO DA DEPENDÊNCIA QUÍMICA: UMA REVISÃO. Revista Interdisciplinar De Estudos Em Saúde, 7(1), 205–219. https://doi.org/10.33362/ries.v7i1.1124

Edição

Seção

Abordagem interdisciplinar da Farmácia em Saúde